[Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].

Abstract

TS-1, an anticancer, antimetabolis agent, has shown clinically superior antitumor activity against unresectable advanced or recurrent gastric cancer (UARG). A biological response modifier, lentinan (LNT) prolonged the survival period of patients with UARG when combined with tegafur (FT). To assess the efficacy, the safety and prognostic factors of chemo… (More)

Topics

Cite this paper

@article{Nimura2003PilotSO, title={[Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].}, author={Hiroshi Nimura and Norio Mitsumori and Shigeru Tsukagoshi and M. Nakajima and Yutaka Atomi and Satoshi Suzuki and Mitsuo Kusano and Toshiro Yoshiyuki and Akira Tokunaga}, journal={Gan to kagaku ryoho. Cancer & chemotherapy}, year={2003}, volume={30 9}, pages={1289-96} }